259 related articles for article (PubMed ID: 24841552)
1. Corticotropin-releasing factor induces immune escape of cervical cancer cells by downregulation of NKG2D.
Song H; Park H; Park G; Kim YS; Lee HK; Jin DH; Kang HS; Cho DH; Hur D
Oncol Rep; 2014 Jul; 32(1):425-30. PubMed ID: 24841552
[TBL] [Abstract][Full Text] [Related]
2. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
Song H; Kim J; Cosman D; Choi I
Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
[TBL] [Abstract][Full Text] [Related]
3. Soluble ligands for the NKG2D receptor are released during HIV-1 infection and impair NKG2D expression and cytotoxicity of NK cells.
Matusali G; Tchidjou HK; Pontrelli G; Bernardi S; D'Ettorre G; Vullo V; Buonomini AR; Andreoni M; Santoni A; Cerboni C; Doria M
FASEB J; 2013 Jun; 27(6):2440-50. PubMed ID: 23395909
[TBL] [Abstract][Full Text] [Related]
4. Interferon-gamma down-regulates NKG2D ligand expression and impairs the NKG2D-mediated cytolysis of MHC class I-deficient melanoma by natural killer cells.
Schwinn N; Vokhminova D; Sucker A; Textor S; Striegel S; Moll I; Nausch N; Tuettenberg J; Steinle A; Cerwenka A; Schadendorf D; Paschen A
Int J Cancer; 2009 Apr; 124(7):1594-604. PubMed ID: 19089914
[TBL] [Abstract][Full Text] [Related]
5. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
6. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
Waldhauer I; Steinle A
Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia downregulates the expression of cell surface MICA without increasing soluble MICA in osteosarcoma cells in a HIF-1α-dependent manner.
Yamada N; Yamanegi K; Ohyama H; Hata M; Nakasho K; Futani H; Okamura H; Terada N
Int J Oncol; 2012 Dec; 41(6):2005-12. PubMed ID: 22992985
[TBL] [Abstract][Full Text] [Related]
8. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
[TBL] [Abstract][Full Text] [Related]
9. Differential NKG2D binding to highly related human NKG2D ligands ULBP2 and RAET1G is determined by a single amino acid in the alpha2 domain.
Wittenbrink M; Spreu J; Steinle A
Eur J Immunol; 2009 Jun; 39(6):1642-51. PubMed ID: 19424970
[TBL] [Abstract][Full Text] [Related]
10. Effects of human cytomegalovirus infection on ligands for the activating NKG2D receptor of NK cells: up-regulation of UL16-binding protein (ULBP)1 and ULBP2 is counteracted by the viral UL16 protein.
Rölle A; Mousavi-Jazi M; Eriksson M; Odeberg J; Söderberg-Nauclér C; Cosman D; Kärre K; Cerboni C
J Immunol; 2003 Jul; 171(2):902-8. PubMed ID: 12847260
[TBL] [Abstract][Full Text] [Related]
11. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
[TBL] [Abstract][Full Text] [Related]
12. Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity.
Pende D; Rivera P; Marcenaro S; Chang CC; Biassoni R; Conte R; Kubin M; Cosman D; Ferrone S; Moretta L; Moretta A
Cancer Res; 2002 Nov; 62(21):6178-86. PubMed ID: 12414645
[TBL] [Abstract][Full Text] [Related]
13. RAET1E2, a soluble isoform of the UL16-binding protein RAET1E produced by tumor cells, inhibits NKG2D-mediated NK cytotoxicity.
Cao W; Xi X; Hao Z; Li W; Kong Y; Cui L; Ma C; Ba D; He W
J Biol Chem; 2007 Jun; 282(26):18922-8. PubMed ID: 17470428
[TBL] [Abstract][Full Text] [Related]
14. Induction of NKG2D ligands and increased sensitivity of tumor cells to NK cell-mediated cytotoxicity by hematoporphyrin-based photodynamic therapy.
Park MJ; Bae JH; Chung JS; Kim SH; Kang CD
Immunol Invest; 2011; 40(4):367-82. PubMed ID: 21314289
[TBL] [Abstract][Full Text] [Related]
15. Generation of soluble NKG2D ligands: proteolytic cleavage, exosome secretion and functional implications.
Chitadze G; Bhat J; Lettau M; Janssen O; Kabelitz D
Scand J Immunol; 2013 Aug; 78(2):120-9. PubMed ID: 23679194
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MMP activity can restore NKG2D ligand expression in gastric cancer, leading to improved NK cell susceptibility.
Shiraishi K; Mimura K; Kua LF; Koh V; Siang LK; Nakajima S; Fujii H; Shabbir A; Yong WP; So J; Takenoshita S; Kono K
J Gastroenterol; 2016 Dec; 51(12):1101-1111. PubMed ID: 27002316
[TBL] [Abstract][Full Text] [Related]
17. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2.
Textor S; Fiegler N; Arnold A; Porgador A; Hofmann TG; Cerwenka A
Cancer Res; 2011 Sep; 71(18):5998-6009. PubMed ID: 21764762
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate.
Armeanu S; Bitzer M; Lauer UM; Venturelli S; Pathil A; Krusch M; Kaiser S; Jobst J; Smirnow I; Wagner A; Steinle A; Salih HR
Cancer Res; 2005 Jul; 65(14):6321-9. PubMed ID: 16024634
[TBL] [Abstract][Full Text] [Related]
19. [Expression of NKG2D ligands in multidrug-resistant nasopharyngeal carcinoma cell line CNE2/DDP and their effects on cytotoxicity of natural killer cells].
Mei JZ; Guo KY; Wei HM; Song CY
Nan Fang Yi Ke Da Xue Xue Bao; 2007 Jun; 27(6):887-9. PubMed ID: 17584663
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein-90 inhibitors increase MHC class I-related chain A and B ligand expression on multiple myeloma cells and their ability to trigger NK cell degranulation.
Fionda C; Soriani A; Malgarini G; Iannitto ML; Santoni A; Cippitelli M
J Immunol; 2009 Oct; 183(7):4385-94. PubMed ID: 19748980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
